nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—Clonus—Cisplatin—bone cancer	0.0273	0.106	CcSEcCtD
Lithium—Papilloedema—Cisplatin—bone cancer	0.00988	0.0385	CcSEcCtD
Lithium—Slurred speech—Cisplatin—bone cancer	0.00702	0.0273	CcSEcCtD
Lithium—Blindness—Cisplatin—bone cancer	0.00567	0.0221	CcSEcCtD
Lithium—Taste metallic—Methotrexate—bone cancer	0.00542	0.0211	CcSEcCtD
Lithium—Optic neuritis—Cisplatin—bone cancer	0.00511	0.0199	CcSEcCtD
Lithium—Dysarthria—Cisplatin—bone cancer	0.00332	0.0129	CcSEcCtD
Lithium—Body temperature increased—Carboplatin—bone cancer	0.00302	0.0118	CcSEcCtD
Lithium—Blindness—Epirubicin—bone cancer	0.00291	0.0113	CcSEcCtD
Lithium—Folliculitis—Methotrexate—bone cancer	0.00274	0.0107	CcSEcCtD
Lithium—Psoriasis—Methotrexate—bone cancer	0.00274	0.0107	CcSEcCtD
Lithium—Blindness—Doxorubicin—bone cancer	0.0027	0.0105	CcSEcCtD
Lithium—Optic neuritis—Epirubicin—bone cancer	0.00262	0.0102	CcSEcCtD
Lithium—Polyuria—Cisplatin—bone cancer	0.0026	0.0101	CcSEcCtD
Lithium—Psoriasis—Epirubicin—bone cancer	0.00257	0.00999	CcSEcCtD
Lithium—Folliculitis—Epirubicin—bone cancer	0.00257	0.00999	CcSEcCtD
Lithium—Optic neuritis—Doxorubicin—bone cancer	0.00243	0.00945	CcSEcCtD
Lithium—Folliculitis—Doxorubicin—bone cancer	0.00237	0.00924	CcSEcCtD
Lithium—Psoriasis—Doxorubicin—bone cancer	0.00237	0.00924	CcSEcCtD
Lithium—Hypercalcaemia—Epirubicin—bone cancer	0.00232	0.00904	CcSEcCtD
Lithium—Stupor—Methotrexate—bone cancer	0.00231	0.00899	CcSEcCtD
Lithium—Nystagmus—Epirubicin—bone cancer	0.00226	0.00879	CcSEcCtD
Lithium—Skin ulcer—Methotrexate—bone cancer	0.00221	0.00862	CcSEcCtD
Lithium—Albuminuria—Epirubicin—bone cancer	0.00216	0.00841	CcSEcCtD
Lithium—Hypercalcaemia—Doxorubicin—bone cancer	0.00215	0.00836	CcSEcCtD
Lithium—Scotoma—Epirubicin—bone cancer	0.00212	0.00827	CcSEcCtD
Lithium—Dehydration—Cisplatin—bone cancer	0.00212	0.00826	CcSEcCtD
Lithium—Nystagmus—Doxorubicin—bone cancer	0.00209	0.00813	CcSEcCtD
Lithium—Skin ulcer—Epirubicin—bone cancer	0.00207	0.00807	CcSEcCtD
Lithium—Albuminuria—Doxorubicin—bone cancer	0.002	0.00778	CcSEcCtD
Lithium—Glycosuria—Epirubicin—bone cancer	0.00199	0.00775	CcSEcCtD
Lithium—Scotoma—Doxorubicin—bone cancer	0.00197	0.00765	CcSEcCtD
Lithium—Skin ulcer—Doxorubicin—bone cancer	0.00192	0.00746	CcSEcCtD
Lithium—Oliguria—Methotrexate—bone cancer	0.00187	0.00728	CcSEcCtD
Lithium—Glycosuria—Doxorubicin—bone cancer	0.00184	0.00717	CcSEcCtD
Lithium—Dysarthria—Methotrexate—bone cancer	0.00182	0.00709	CcSEcCtD
Lithium—Oliguria—Epirubicin—bone cancer	0.00175	0.00681	CcSEcCtD
Lithium—Dysarthria—Epirubicin—bone cancer	0.00171	0.00664	CcSEcCtD
Lithium—Depressed level of consciousness—Methotrexate—bone cancer	0.00166	0.00648	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—bone cancer	0.00164	0.0064	CcSEcCtD
Lithium—Oliguria—Doxorubicin—bone cancer	0.00162	0.00631	CcSEcCtD
Lithium—Bradycardia—Cisplatin—bone cancer	0.00161	0.00625	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—bone cancer	0.00158	0.00614	CcSEcCtD
Lithium—Coma—Methotrexate—bone cancer	0.00158	0.00613	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—bone cancer	0.00157	0.0061	CcSEcCtD
Lithium—Urine output increased—Methotrexate—bone cancer	0.00156	0.00607	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—bone cancer	0.00152	0.00592	CcSEcCtD
Lithium—GSK3B—connective tissue—bone cancer	0.0015	0.155	CbGeAlD
Lithium—Coma—Epirubicin—bone cancer	0.00147	0.00574	CcSEcCtD
Lithium—Tinnitus—Cisplatin—bone cancer	0.00147	0.00573	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—bone cancer	0.00145	0.00564	CcSEcCtD
Lithium—Polyuria—Methotrexate—bone cancer	0.00143	0.00555	CcSEcCtD
Lithium—Hypertonia—Epirubicin—bone cancer	0.00141	0.0055	CcSEcCtD
Lithium—Arrhythmia—Cisplatin—bone cancer	0.00141	0.00549	CcSEcCtD
Lithium—Alopecia—Cisplatin—bone cancer	0.00139	0.00543	CcSEcCtD
Lithium—GSK3A—B Cell Activation—KIT—bone cancer	0.00139	0.00189	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—MDM2—bone cancer	0.00137	0.00187	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—BRAF—bone cancer	0.00137	0.00187	CbGpPWpGaD
Lithium—Coma—Doxorubicin—bone cancer	0.00136	0.00531	CcSEcCtD
Lithium—GSK3B—Cell Cycle—MDM2—bone cancer	0.00136	0.00185	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—MDM2—bone cancer	0.00136	0.00185	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—MDM2—bone cancer	0.00136	0.00185	CbGpPWpGaD
Lithium—Flatulence—Cisplatin—bone cancer	0.00135	0.00527	CcSEcCtD
Lithium—GSK3B—LPA receptor mediated events—EGFR—bone cancer	0.00135	0.00184	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00134	0.00183	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CYP3A4—bone cancer	0.00134	0.00183	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—TP53—bone cancer	0.00134	0.00182	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—MDM2—bone cancer	0.00134	0.00182	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—KIT—bone cancer	0.00133	0.00181	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.00133	0.00181	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ATF1—bone cancer	0.00133	0.00181	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—MDM2—bone cancer	0.00133	0.00181	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—bone cancer	0.00133	0.00181	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GNA11—bone cancer	0.00132	0.0018	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—JUN—bone cancer	0.00132	0.0018	CbGpPWpGaD
Lithium—Hypertonia—Doxorubicin—bone cancer	0.00131	0.00509	CcSEcCtD
Lithium—GSK3A—connective tissue—bone cancer	0.00131	0.135	CbGeAlD
Lithium—GSK3A—PI-3K cascade—EGFR—bone cancer	0.0013	0.00177	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—bone cancer	0.0013	0.00177	CbGpPWpGaD
Lithium—Vision blurred—Cisplatin—bone cancer	0.00129	0.00504	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—MDM2—bone cancer	0.00129	0.00176	CbGpPWpGaD
Lithium—Tremor—Cisplatin—bone cancer	0.00129	0.00501	CcSEcCtD
Lithium—Lethargy—Methotrexate—bone cancer	0.00128	0.00497	CcSEcCtD
Lithium—GSK3A—Downstream signal transduction—MDM2—bone cancer	0.00128	0.00174	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KIT—bone cancer	0.00127	0.00174	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—MDM2—bone cancer	0.00127	0.00173	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—EGFR—bone cancer	0.00127	0.00173	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—MDM2—bone cancer	0.00126	0.00172	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—MDM2—bone cancer	0.00126	0.00171	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—EGFR—bone cancer	0.00126	0.00171	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KIT—bone cancer	0.00125	0.00171	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.00125	0.0017	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	0.00124	0.00169	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—JUN—bone cancer	0.00123	0.00168	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	0.00123	0.00167	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—TP53—bone cancer	0.00121	0.00165	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—MMP9—bone cancer	0.0012	0.00164	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KIT—bone cancer	0.0012	0.00163	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CYP3A4—bone cancer	0.0012	0.00163	CbGpPWpGaD
Lithium—Lethargy—Epirubicin—bone cancer	0.00119	0.00465	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR—KIT—bone cancer	0.00119	0.00162	CbGpPWpGaD
Lithium—Convulsion—Cisplatin—bone cancer	0.00119	0.00463	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—KIT—bone cancer	0.00119	0.00162	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—MDM2—bone cancer	0.00118	0.00161	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.00118	0.00161	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—MDM2—bone cancer	0.00118	0.00161	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—GSTP1—bone cancer	0.00118	0.00161	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—JUN—bone cancer	0.00118	0.00161	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KIT—bone cancer	0.00118	0.00161	CbGpPWpGaD
Lithium—Ataxia—Methotrexate—bone cancer	0.00118	0.00458	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—MDM2—bone cancer	0.00117	0.0016	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00117	0.00159	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	0.00116	0.00158	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—MDM2—bone cancer	0.00116	0.00158	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—MDM2—bone cancer	0.00116	0.00158	CbGpPWpGaD
Lithium—Discomfort—Cisplatin—bone cancer	0.00116	0.0045	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—JUN—bone cancer	0.00115	0.00157	CbGpPWpGaD
Lithium—GRIA3—spinal cord—bone cancer	0.00115	0.119	CbGeAlD
Lithium—IMPA2—Metabolism—GSTP1—bone cancer	0.00115	0.00156	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—MDM2—bone cancer	0.00115	0.00156	CbGpPWpGaD
Lithium—Oedema—Cisplatin—bone cancer	0.00112	0.00436	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR—BRAF—bone cancer	0.00112	0.00153	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—JUN—bone cancer	0.00112	0.00153	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—JUN—bone cancer	0.00111	0.00152	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—MET—bone cancer	0.00111	0.00152	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.00111	0.00152	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	0.00111	0.00151	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KIT—bone cancer	0.00111	0.00151	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KIT—bone cancer	0.00111	0.00151	CbGpPWpGaD
Lithium—Lethargy—Doxorubicin—bone cancer	0.00111	0.0043	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—EIF2S1—bone cancer	0.0011	0.00151	CbGpPWpGaD
Lithium—Ataxia—Epirubicin—bone cancer	0.0011	0.00429	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—KIT—bone cancer	0.0011	0.0015	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—MDM2—bone cancer	0.00109	0.00149	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KIT—bone cancer	0.00109	0.00149	CbGpPWpGaD
Lithium—Dehydration—Epirubicin—bone cancer	0.00109	0.00424	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—KIT—bone cancer	0.00109	0.00148	CbGpPWpGaD
Lithium—Dry skin—Epirubicin—bone cancer	0.00107	0.00418	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.00107	0.00146	CbGpPWpGaD
Lithium—Anorexia—Cisplatin—bone cancer	0.00107	0.00416	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—CDK4—bone cancer	0.00106	0.00145	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bone cancer	0.00106	0.00145	CbGpPWpGaD
Lithium—IMPA2—tendon—bone cancer	0.00105	0.109	CbGeAlD
Lithium—GSK3B—Signaling by SCF-KIT—MDM2—bone cancer	0.00105	0.00143	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.00105	0.00143	CbGpPWpGaD
Lithium—Hypotension—Cisplatin—bone cancer	0.00105	0.00408	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—BRAF—bone cancer	0.00104	0.00142	CbGpPWpGaD
Lithium—Gastritis—Epirubicin—bone cancer	0.00104	0.00403	CcSEcCtD
Lithium—GSK3B—Androgen receptor signaling pathway—EGFR—bone cancer	0.00104	0.00141	CbGpPWpGaD
Lithium—Muscular weakness—Epirubicin—bone cancer	0.00103	0.00402	CcSEcCtD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	0.00103	0.0014	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KIT—bone cancer	0.00103	0.0014	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ATF1—bone cancer	0.00103	0.0014	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KIT—bone cancer	0.00102	0.00139	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GSTP1—bone cancer	0.00102	0.00139	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00102	0.00398	CcSEcCtD
Lithium—IMPA2—bone marrow—bone cancer	0.00102	0.106	CbGeAlD
Lithium—Ataxia—Doxorubicin—bone cancer	0.00102	0.00397	CcSEcCtD
Lithium—Dehydration—Doxorubicin—bone cancer	0.00101	0.00392	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—MDM2—bone cancer	0.001	0.00137	CbGpPWpGaD
Lithium—Erectile dysfunction—Methotrexate—bone cancer	0.000996	0.00388	CcSEcCtD
Lithium—GSK3B—spinal cord—bone cancer	0.000996	0.103	CbGeAlD
Lithium—Dry skin—Doxorubicin—bone cancer	0.000993	0.00387	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—MDM2—bone cancer	0.000987	0.00135	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—BRAF—bone cancer	0.000986	0.00134	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.000983	0.00134	CbGpPWpGaD
Lithium—Decreased appetite—Cisplatin—bone cancer	0.000974	0.00379	CcSEcCtD
Lithium—GSK3A—Signaling by SCF-KIT—EGFR—bone cancer	0.000969	0.00132	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000967	0.00132	CbGpPWpGaD
Lithium—Drowsiness—Methotrexate—bone cancer	0.000964	0.00375	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—BRAF—bone cancer	0.000962	0.00131	CbGpPWpGaD
Lithium—Gastritis—Doxorubicin—bone cancer	0.000959	0.00373	CcSEcCtD
Lithium—GSK3B—PI-3K cascade—EGFR—bone cancer	0.000958	0.00131	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—bone cancer	0.000956	0.0013	CbGpPWpGaD
Lithium—Muscular weakness—Doxorubicin—bone cancer	0.000956	0.00372	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—MDM2—bone cancer	0.000943	0.00129	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—MDM2—bone cancer	0.000938	0.00128	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—EGFR—bone cancer	0.000936	0.00128	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—MDM2—bone cancer	0.000933	0.00127	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—MDM2—bone cancer	0.000929	0.00127	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—EGFR—bone cancer	0.000928	0.00127	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.000928	0.00127	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000928	0.00126	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000924	0.00126	CbGpPWpGaD
Lithium—Feeling abnormal—Cisplatin—bone cancer	0.000924	0.0036	CcSEcCtD
Lithium—Weight increased—Epirubicin—bone cancer	0.000921	0.00359	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000918	0.00125	CbGpPWpGaD
Lithium—Weight decreased—Epirubicin—bone cancer	0.000916	0.00356	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	0.000916	0.00125	CbGpPWpGaD
Lithium—Hyperglycaemia—Epirubicin—bone cancer	0.000913	0.00355	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB4—EGFR—bone cancer	0.000913	0.00124	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	0.000907	0.00124	CbGpPWpGaD
Lithium—Drowsiness—Epirubicin—bone cancer	0.000902	0.00351	CcSEcCtD
Lithium—GSK3A—tendon—bone cancer	0.000898	0.0929	CbGeAlD
Lithium—GSK3B—BDNF signaling pathway—JUN—bone cancer	0.000896	0.00122	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—MMP9—bone cancer	0.000886	0.00121	CbGpPWpGaD
Lithium—Body temperature increased—Cisplatin—bone cancer	0.000886	0.00345	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—MDM2—bone cancer	0.000874	0.00119	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—MDM2—bone cancer	0.000874	0.00119	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.000874	0.00119	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—EGFR—bone cancer	0.000872	0.00119	CbGpPWpGaD
Lithium—GSK3A—bone marrow—bone cancer	0.000869	0.09	CbGeAlD
Lithium—GSK3A—Signaling by FGFR—EGFR—bone cancer	0.000868	0.00118	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—MDM2—bone cancer	0.000866	0.00118	CbGpPWpGaD
Lithium—GSK3A—spinal cord—bone cancer	0.000866	0.0896	CbGeAlD
Lithium—GSK3A—Signaling by ERBB2—EGFR—bone cancer	0.000863	0.00118	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—EGFR—bone cancer	0.000859	0.00117	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000858	0.00117	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDK4—bone cancer	0.000856	0.00117	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—MDM2—bone cancer	0.000855	0.00117	CbGpPWpGaD
Lithium—Weight increased—Doxorubicin—bone cancer	0.000852	0.00332	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—bone cancer	0.000847	0.0033	CcSEcCtD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	0.000847	0.00115	CbGpPWpGaD
Lithium—Hyperglycaemia—Doxorubicin—bone cancer	0.000845	0.00329	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—bone cancer	0.000835	0.00325	CcSEcCtD
Lithium—Bradycardia—Epirubicin—bone cancer	0.000825	0.00321	CcSEcCtD
Lithium—GSK3B—Insulin Signaling—JUN—bone cancer	0.000824	0.00112	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—MDM2—bone cancer	0.000809	0.0011	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—EGFR—bone cancer	0.000808	0.0011	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	0.000808	0.0011	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—EGFR—bone cancer	0.000808	0.0011	CbGpPWpGaD
Lithium—Tinnitus—Methotrexate—bone cancer	0.000807	0.00314	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—MDM2—bone cancer	0.000806	0.0011	CbGpPWpGaD
Lithium—Asthenia—Cisplatin—bone cancer	0.000804	0.00313	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—EGFR—bone cancer	0.000801	0.00109	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000794	0.00108	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—EGFR—bone cancer	0.00079	0.00108	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—bone cancer	0.000779	0.00106	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—bone cancer	0.000779	0.00106	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000774	0.00106	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000771	0.00105	CbGpPWpGaD
Lithium—Diarrhoea—Cisplatin—bone cancer	0.000767	0.00299	CcSEcCtD
Lithium—Alopecia—Methotrexate—bone cancer	0.000765	0.00298	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—bone cancer	0.000763	0.00297	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—bone cancer	0.000761	0.00104	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.00076	0.00104	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	0.00076	0.00104	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ATF1—bone cancer	0.000758	0.00103	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KIT—bone cancer	0.000756	0.00103	CbGpPWpGaD
Lithium—Tinnitus—Epirubicin—bone cancer	0.000755	0.00294	CcSEcCtD
Lithium—GSK3A—B Cell Activation—EGFR—bone cancer	0.000748	0.00102	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—RB1—bone cancer	0.000744	0.00101	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RGS1—bone cancer	0.000743	0.00101	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GRM4—bone cancer	0.000743	0.00101	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—bone cancer	0.000739	0.00101	CbGpPWpGaD
Lithium—Dysgeusia—Methotrexate—bone cancer	0.000738	0.00287	CcSEcCtD
Lithium—GSK3B—Axon guidance—MET—bone cancer	0.000727	0.000991	CbGpPWpGaD
Lithium—Arrhythmia—Epirubicin—bone cancer	0.000724	0.00282	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—JUN—bone cancer	0.000718	0.000979	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—bone cancer	0.000716	0.000977	CbGpPWpGaD
Lithium—Alopecia—Epirubicin—bone cancer	0.000716	0.00279	CcSEcCtD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	0.000716	0.000976	CbGpPWpGaD
Lithium—Vomiting—Cisplatin—bone cancer	0.000713	0.00277	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—BRAF—bone cancer	0.000711	0.000969	CbGpPWpGaD
Lithium—Vision blurred—Methotrexate—bone cancer	0.00071	0.00276	CcSEcCtD
Lithium—Rash—Cisplatin—bone cancer	0.000707	0.00275	CcSEcCtD
Lithium—Dermatitis—Cisplatin—bone cancer	0.000706	0.00275	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—bone cancer	0.000699	0.00272	CcSEcCtD
Lithium—Flatulence—Epirubicin—bone cancer	0.000695	0.00271	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—bone cancer	0.000691	0.00269	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—JUN—bone cancer	0.000686	0.000935	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000685	0.000934	CbGpPWpGaD
Lithium—GSK3A—Disease—ENO2—bone cancer	0.000684	0.000932	CbGpPWpGaD
Lithium—Vertigo—Methotrexate—bone cancer	0.000677	0.00264	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—EGFR—bone cancer	0.000675	0.00092	CbGpPWpGaD
Lithium—Arrhythmia—Doxorubicin—bone cancer	0.00067	0.00261	CcSEcCtD
Lithium—Nausea—Cisplatin—bone cancer	0.000666	0.00259	CcSEcCtD
Lithium—Vision blurred—Epirubicin—bone cancer	0.000665	0.00259	CcSEcCtD
Lithium—Alopecia—Doxorubicin—bone cancer	0.000662	0.00258	CcSEcCtD
Lithium—Convulsion—Methotrexate—bone cancer	0.000653	0.00254	CcSEcCtD
Lithium—Agitation—Epirubicin—bone cancer	0.000648	0.00252	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—GRM1—bone cancer	0.000644	0.000879	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—bone cancer	0.000644	0.000878	CbGpPWpGaD
Lithium—Flatulence—Doxorubicin—bone cancer	0.000643	0.0025	CcSEcCtD
Lithium—Arthralgia—Methotrexate—bone cancer	0.000642	0.0025	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR—EGFR—bone cancer	0.000641	0.000874	CbGpPWpGaD
Lithium—Dysgeusia—Doxorubicin—bone cancer	0.000639	0.00249	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000638	0.00087	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—bone cancer	0.000638	0.00087	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—bone cancer	0.000635	0.000865	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—MDM2—bone cancer	0.000635	0.000865	CbGpPWpGaD
Lithium—GSK3A—Disease—DHFR—bone cancer	0.000635	0.000865	CbGpPWpGaD
Lithium—Discomfort—Methotrexate—bone cancer	0.000634	0.00247	CcSEcCtD
Lithium—Vertigo—Epirubicin—bone cancer	0.000634	0.00247	CcSEcCtD
Lithium—Syncope—Epirubicin—bone cancer	0.000632	0.00246	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	0.000626	0.000853	CbGpPWpGaD
Lithium—Confusional state—Methotrexate—bone cancer	0.00062	0.00241	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—bone cancer	0.00062	0.00241	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—bone cancer	0.000615	0.00239	CcSEcCtD
Lithium—Convulsion—Epirubicin—bone cancer	0.000611	0.00238	CcSEcCtD
Lithium—GSK3B—Axon guidance—MMP2—bone cancer	0.000606	0.000826	CbGpPWpGaD
Lithium—Arthralgia—Epirubicin—bone cancer	0.0006	0.00234	CcSEcCtD
Lithium—Agitation—Doxorubicin—bone cancer	0.0006	0.00233	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—bone cancer	0.000597	0.000814	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	0.000597	0.000814	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—bone cancer	0.000597	0.000814	CbGpPWpGaD
Lithium—GSK3A—Immune System—ATF1—bone cancer	0.000597	0.000814	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—MDM2—bone cancer	0.000595	0.000812	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—bone cancer	0.000595	0.000811	CbGpPWpGaD
Lithium—Discomfort—Epirubicin—bone cancer	0.000593	0.00231	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—EGFR—bone cancer	0.000592	0.000807	CbGpPWpGaD
Lithium—Dry mouth—Epirubicin—bone cancer	0.000587	0.00229	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000587	0.0008	CbGpPWpGaD
Lithium—Vertigo—Doxorubicin—bone cancer	0.000586	0.00228	CcSEcCtD
Lithium—Anorexia—Methotrexate—bone cancer	0.000586	0.00228	CcSEcCtD
Lithium—Syncope—Doxorubicin—bone cancer	0.000585	0.00228	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—EGFR—bone cancer	0.000584	0.000796	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KIT—bone cancer	0.000583	0.000795	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL3—bone cancer	0.000582	0.000794	CbGpPWpGaD
Lithium—Confusional state—Epirubicin—bone cancer	0.00058	0.00226	CcSEcCtD
Lithium—Oedema—Epirubicin—bone cancer	0.000576	0.00224	CcSEcCtD
Lithium—Hypotension—Methotrexate—bone cancer	0.000575	0.00224	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—bone cancer	0.000573	0.00223	CcSEcCtD
Lithium—Shock—Epirubicin—bone cancer	0.000566	0.0022	CcSEcCtD
Lithium—Convulsion—Doxorubicin—bone cancer	0.000565	0.0022	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—EGFR—bone cancer	0.000564	0.000769	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00056	0.00218	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—KIT—bone cancer	0.00056	0.000764	CbGpPWpGaD
Lithium—Arthralgia—Doxorubicin—bone cancer	0.000556	0.00216	CcSEcCtD
Lithium—GSK3B—B Cell Activation—EGFR—bone cancer	0.000553	0.000754	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—JUN—bone cancer	0.000552	0.000752	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—bone cancer	0.000551	0.000751	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RGS1—bone cancer	0.000549	0.000749	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GRM4—bone cancer	0.000549	0.000749	CbGpPWpGaD
Lithium—Discomfort—Doxorubicin—bone cancer	0.000549	0.00214	CcSEcCtD
Lithium—Anorexia—Epirubicin—bone cancer	0.000549	0.00214	CcSEcCtD
Lithium—Somnolence—Methotrexate—bone cancer	0.000547	0.00213	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—bone cancer	0.000543	0.00212	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—bone cancer	0.000541	0.00211	CcSEcCtD
Lithium—Hypotension—Epirubicin—bone cancer	0.000538	0.00209	CcSEcCtD
Lithium—Confusional state—Doxorubicin—bone cancer	0.000537	0.00209	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—bone cancer	0.000535	0.00208	CcSEcCtD
Lithium—Oedema—Doxorubicin—bone cancer	0.000533	0.00207	CcSEcCtD
Lithium—Fatigue—Methotrexate—bone cancer	0.00053	0.00206	CcSEcCtD
Lithium—IMPA1—Metabolism—PTGS2—bone cancer	0.00053	0.000722	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	0.000529	0.000721	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000524	0.00204	CcSEcCtD
Lithium—Shock—Doxorubicin—bone cancer	0.000524	0.00204	CcSEcCtD
Lithium—GSK3B—Developmental Biology—MET—bone cancer	0.000519	0.000707	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CDK4—bone cancer	0.000519	0.000707	CbGpPWpGaD
Lithium—Somnolence—Epirubicin—bone cancer	0.000512	0.00199	CcSEcCtD
Lithium—Anorexia—Doxorubicin—bone cancer	0.000508	0.00198	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—bone cancer	0.000507	0.00197	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—bone cancer	0.000507	0.00197	CcSEcCtD
Lithium—GSK3B—Disease—ENO2—bone cancer	0.000505	0.000689	CbGpPWpGaD
Lithium—Gastrointestinal pain—Methotrexate—bone cancer	0.000503	0.00196	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—bone cancer	0.0005	0.00195	CcSEcCtD
Lithium—Hypotension—Doxorubicin—bone cancer	0.000498	0.00194	CcSEcCtD
Lithium—Fatigue—Epirubicin—bone cancer	0.000496	0.00193	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—bone cancer	0.000486	0.00189	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—bone cancer	0.000486	0.00189	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000485	0.00189	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—GRM1—bone cancer	0.000476	0.000649	CbGpPWpGaD
Lithium—Feeling abnormal—Epirubicin—bone cancer	0.000474	0.00185	CcSEcCtD
Lithium—Somnolence—Doxorubicin—bone cancer	0.000473	0.00184	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—bone cancer	0.000471	0.00183	CcSEcCtD
Lithium—GSK3B—Disease—DHFR—bone cancer	0.000469	0.000639	CbGpPWpGaD
Lithium—Dyspepsia—Doxorubicin—bone cancer	0.000469	0.00182	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—bone cancer	0.000463	0.0018	CcSEcCtD
Lithium—GSK3A—Disease—TGFBR2—bone cancer	0.00046	0.000627	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—MDM2—bone cancer	0.00046	0.000626	CbGpPWpGaD
Lithium—Fatigue—Doxorubicin—bone cancer	0.000459	0.00179	CcSEcCtD
Lithium—GSK3B—Axon guidance—MMP9—bone cancer	0.000456	0.000621	CbGpPWpGaD
Lithium—Body temperature increased—Epirubicin—bone cancer	0.000455	0.00177	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—bone cancer	0.000455	0.00177	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—SMO—bone cancer	0.000454	0.000619	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—bone cancer	0.000453	0.000618	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—bone cancer	0.000452	0.000616	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—MDM2—bone cancer	0.000441	0.000602	CbGpPWpGaD
Lithium—GSK3B—Immune System—ATF1—bone cancer	0.000441	0.000602	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—bone cancer	0.000441	0.00172	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—bone cancer	0.000439	0.00171	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—bone cancer	0.000435	0.0017	CcSEcCtD
Lithium—GSK3B—Developmental Biology—MMP2—bone cancer	0.000433	0.00059	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KIT—bone cancer	0.000431	0.000588	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL3—bone cancer	0.00043	0.000587	CbGpPWpGaD
Lithium—Abdominal pain—Doxorubicin—bone cancer	0.000421	0.00164	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—bone cancer	0.000421	0.00164	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—bone cancer	0.000421	0.00164	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—GNA11—bone cancer	0.000415	0.000566	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KIT—bone cancer	0.000414	0.000564	CbGpPWpGaD
Lithium—Asthenia—Epirubicin—bone cancer	0.000413	0.00161	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—EGFR—bone cancer	0.000407	0.000555	CbGpPWpGaD
Lithium—Dizziness—Methotrexate—bone cancer	0.000407	0.00158	CcSEcCtD
Lithium—GSK3A—Innate Immune System—JUN—bone cancer	0.000399	0.000545	CbGpPWpGaD
Lithium—Diarrhoea—Epirubicin—bone cancer	0.000394	0.00153	CcSEcCtD
Lithium—Vomiting—Methotrexate—bone cancer	0.000391	0.00152	CcSEcCtD
Lithium—Rash—Methotrexate—bone cancer	0.000388	0.00151	CcSEcCtD
Lithium—Dermatitis—Methotrexate—bone cancer	0.000387	0.00151	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—ATF1—bone cancer	0.000386	0.000526	CbGpPWpGaD
Lithium—Headache—Methotrexate—bone cancer	0.000385	0.0015	CcSEcCtD
Lithium—Asthenia—Doxorubicin—bone cancer	0.000382	0.00149	CcSEcCtD
Lithium—Dizziness—Epirubicin—bone cancer	0.000381	0.00148	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—IL3—bone cancer	0.000376	0.000513	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—bone cancer	0.000368	0.000502	CbGpPWpGaD
Lithium—Vomiting—Epirubicin—bone cancer	0.000366	0.00142	CcSEcCtD
Lithium—Nausea—Methotrexate—bone cancer	0.000365	0.00142	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—bone cancer	0.000364	0.00142	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—TP53—bone cancer	0.000364	0.000497	CbGpPWpGaD
Lithium—Rash—Epirubicin—bone cancer	0.000363	0.00141	CcSEcCtD
Lithium—Dermatitis—Epirubicin—bone cancer	0.000363	0.00141	CcSEcCtD
Lithium—Headache—Epirubicin—bone cancer	0.000361	0.0014	CcSEcCtD
Lithium—Dizziness—Doxorubicin—bone cancer	0.000352	0.00137	CcSEcCtD
Lithium—Nausea—Epirubicin—bone cancer	0.000342	0.00133	CcSEcCtD
Lithium—GSK3A—Immune System—KIT—bone cancer	0.00034	0.000463	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFBR2—bone cancer	0.00034	0.000463	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MDM2—bone cancer	0.00034	0.000463	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—bone cancer	0.000339	0.00132	CcSEcCtD
Lithium—Rash—Doxorubicin—bone cancer	0.000336	0.00131	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—SMO—bone cancer	0.000336	0.000457	CbGpPWpGaD
Lithium—Dermatitis—Doxorubicin—bone cancer	0.000335	0.00131	CcSEcCtD
Lithium—Headache—Doxorubicin—bone cancer	0.000334	0.0013	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—MDM2—bone cancer	0.000326	0.000445	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—bone cancer	0.000325	0.000443	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFBR2—bone cancer	0.000322	0.000439	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—bone cancer	0.000316	0.00123	CcSEcCtD
Lithium—GSK3A—Innate Immune System—EGFR—bone cancer	0.000314	0.000428	CbGpPWpGaD
Lithium—GSK3A—Disease—KIT—bone cancer	0.000314	0.000428	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNA11—bone cancer	0.000307	0.000418	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1R—bone cancer	0.000303	0.000413	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—bone cancer	0.000302	0.000411	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—JUN—bone cancer	0.000295	0.000402	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—bone cancer	0.000295	0.000402	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ATF1—bone cancer	0.000285	0.000389	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL3—bone cancer	0.000278	0.000379	CbGpPWpGaD
Lithium—GSK3A—Immune System—MDM2—bone cancer	0.000268	0.000365	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—bone cancer	0.000263	0.000358	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIT—bone cancer	0.000251	0.000342	CbGpPWpGaD
Lithium—GSK3A—Disease—MDM2—bone cancer	0.000247	0.000337	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—bone cancer	0.000238	0.000325	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFBR2—bone cancer	0.000238	0.000324	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—bone cancer	0.000233	0.000317	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—bone cancer	0.000232	0.000316	CbGpPWpGaD
Lithium—GSK3B—Disease—KIT—bone cancer	0.000232	0.000316	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—bone cancer	0.000224	0.000305	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—bone cancer	0.000223	0.000304	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIT—bone cancer	0.00022	0.0003	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—bone cancer	0.000218	0.000297	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—bone cancer	0.000207	0.000282	CbGpPWpGaD
Lithium—GSK3B—Immune System—MDM2—bone cancer	0.000198	0.00027	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—bone cancer	0.000183	0.000249	CbGpPWpGaD
Lithium—GSK3B—Disease—MDM2—bone cancer	0.000183	0.000249	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—bone cancer	0.000176	0.00024	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MDM2—bone cancer	0.000173	0.000236	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—bone cancer	0.000172	0.000234	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—bone cancer	0.000169	0.00023	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIT—bone cancer	0.000162	0.000221	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—bone cancer	0.000153	0.000208	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—bone cancer	0.00015	0.000205	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—bone cancer	0.000146	0.0002	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—bone cancer	0.000135	0.000184	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MDM2—bone cancer	0.000128	0.000174	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—bone cancer	0.000125	0.00017	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—bone cancer	0.000118	0.000161	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—bone cancer	0.000111	0.000152	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—bone cancer	0.000108	0.000147	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—bone cancer	9.93e-05	0.000135	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—bone cancer	8.74e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—bone cancer	7.34e-05	0.0001	CbGpPWpGaD
